Xinda pd-1 first quarter sales of 400 million! Domestic strength competition began

the end of last year, Xinda BioPD-1 negotiated a health-care catalog, and sales of the drug grew more than expected in the first quarter of this year, highlighting the importance of health-care releases for innovative drugs in the country. Domestic PD-(L)1 market blue sea, innovative pharmaceutical companies research and development enthusiasm, track congestion, in the health care negotiations, fee control and other policies, one after another into the pressure also appeared ...After entering the health insurance, Xinda PD-1 sales in the first quarter of 400 millionOn April 23, Xinda Bio announced that in the first quarter of 2020, Dharbershu (Xindili single anti-injection) sales revenue of about 400 million yuan. Despite the new crown pneumonia outbreak, Dabershu sales continued last year's strong. According to the 2019 financial results released by Xinda, the first year of sales of Daboshu, which went public in March last year, exceeded Rmb1bn.Xinhua said Dabershu's inclusion in the national health insurance directory would further borrow from its current sales performance and continue to make a significant contribution to the group's revenues and profits. Its founder, chairman and chief executive, Yu Dechao, also expects Dabshu's sales performance this year to be better than last year's.Notably, a Credit Suitly report today said Mr Dabershu's first-quarter sales forecast was about 30 per cent higher than the bank's forecast. Credit Raith estimates that sales of the drug will increase for the rest of the year, raising its full-year sales forecast from 1.51 billion yuan to 1.96 billion yuan, and raising its target price from 38 yuan to 41.5 yuan. . .On November 28 last year, the National Health Insurance Administration released a list of successful drugs for the 2019 health care negotiations. Among them, Thaksin Dilli single anti-injection became the first and only PD-1 to enter the health insurance purpose. Junshi Biological Tuyi, Merca East K medicine and other unexpected out, Hengrui Erika, Baiji Shenzhou Baizean due to the late approval time failed to enter the negotiations.Thysta PD-1 has reduced its price by 63.73% to below 100,000 per year from January 1, 2020. Now, judging by Xinda's first-quarter sales revenue, Dabershu's entry into the health-care catalog, while prices have fallen, has achieved rapid volume and has not been materially affected during the outbreak.PD-(L)1 is highly competitive, Hengrui PD-1 1 domestically listedPD-(L)1, in addition to the above-mentioned four domestic products, as well as Peppa Squire's Opdivo and Mercado's Keytruda, as well as AstraZeneta's Im Finzi (PD-L1) and Roche's Te Centri q (PD-L1). More than a dozen PD-(L)1s are expected to go on sale in the next two years. Moreover, expanding the scope of adaptation is also the direction of the current focus of major pharmaceutical companies.For domestic PD-1 companies alone, the data show that Junshi is conducting more than 30 clinical trials of Terripri monotherapy and co-treatments worldwide, including 14 key registered clinical trials. Xinda has conducted more than 20 clinical studies in China and the United States on Xindili monoanti, including more than 10 key registered clinical studies. Hengrui is currently conducting 25 clinical studies in China to evaluate carelliju single-drug or combined different treatments. There are 15 potentially registered clinical trials in China and around the world, including 11 Phase 3 clinical trials and 4 key Phase 2 clinical trials covering high-risk cancers such as lung cancer, liver cancer, esophageal squamous cell carcinoma, and stomach cancer.At present, in the domestic Opdivo and Keytruda have been approved 3 and 4 adaptive disorders, domestic PD-1 adaptive disorders are not more than 2. Toyi and Daboshu were approved for only one adaptive disorder, melanoma, relapsed/recurring classic Hodgkin's lymphoma. Despite the short time to market, Henri and Baiji Shenzhou's PD-1 have both received 2 allergens, of which Erica has been approved for classic Hodgkin's lymphoma and hepatocellular carcinoma, and Bai Zean has been approved for typical Hodgkin's lymphoma and local late stage or metastatic urethroid cancer. Domestic PD-(L)1 competition is heating up, for enterprises spending heavily on research and development investment, the greater the risk.Recently, Xinda, Junshi have announced PD-1 sales last year, Thyda Burshu last year sales of more than 1 billion yuan, Junshi Tuoyi sales revenue of 774 million yuan. In addition, Henri Erika was also reported to have sales of more than 1 billion yuan. It is not surprising that Junshi PD-1 was overtaken by later, from the point of view of clinical needs, Toyi is currently approved for adaptive melanoma market space in China is limited. At the time, this was also considered by the industry to be one of the reasons for the failure to enter the health insurance directory.Wanlian Securities expects that as more and more domestic and foreign varieties join the listed product ladder, taking into account the increased market competition brought about by the price reduction overlay health insurance support, PD-(L)1 product market penetration rate is expected to increase rapidly, the domestic market terminal size is expected to reach 50 billion yuan. How are tens of billions of markets divided? In the highly competitive track, in addition to the policy, adaptive aspects of the competition, the domestic PD-(L)1 enterprises need to come up with what strength?In less than half a year after the listing was reported to have broken 1 billion Henri Erika, the industry is considered or will be the future of China's PD-1 market the biggest winner. Recently, Hengrui PD-1 officially declared "going out to sea", on April 20, Hengrui Pharma announced that it had reached an agreement with Korea's Crystal Genomics Inc. to license the Korean research and development and commercialization rights of Karry Zhu single-resistance to the company, a move that could accelerate its becoming a PD-1 market overlord.Citic Capital Securities pointed out that the PD-1 single-resistance overseas authorization for Hengrui, on the one hand, can obtain a milestone plus share of the proceeds, on the other hand, is also one of its innovative drug global strategy, but also to help Hengrui build brand influence overseas. It is not hard to see that innovative pharmaceutical companies with global development capabilities have a competitive advantage on the PD-(L)1 circuit.
(Sina Pharmaceutical News)